1. Home
  2. PMCB vs GITS Comparison

PMCB vs GITS Comparison

Compare PMCB & GITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PharmaCyte  Biotech Inc.

PMCB

PharmaCyte Biotech Inc.

HOLD

Current Price

$0.44

Market Cap

6.3M

Sector

Health Care

ML Signal

HOLD

Logo Global Interactive Technologies Inc.

GITS

Global Interactive Technologies Inc.

N/A

Current Price

$2.03

Market Cap

7.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
PMCB
GITS
Founded
1996
2018
Country
United States
South Korea
Employees
N/A
5
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3M
7.2M
IPO Year
2001
N/A

Fundamental Metrics

Financial Performance
Metric
PMCB
GITS
Price
$0.44
$2.03
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 302.6K
21.4K
Earning Date
03-17-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.33
$0.66
52 Week High
$1.51
$7.09

Technical Indicators

Market Signals
Indicator
PMCB
GITS
Relative Strength Index (RSI) 44.03 47.78
Support Level $0.33 $1.91
Resistance Level $0.77 $2.62
Average True Range (ATR) 0.05 0.17
MACD 0.01 -0.02
Stochastic Oscillator 63.10 12.50

Price Performance

Historical Comparison
PMCB
GITS

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.

About GITS Global Interactive Technologies Inc.

Global Interactive Technologies Inc is operating and developing Faning, a digital fan engagement platform focused on Korean entertainment and culture, including K-pop. Faning is designed to support online fan communities, user interaction, multilingual communication, and digital engagement experiences across mobile and web-based services. The platform evolved from the legacy Fantoo platform ecosystem. The Company's primary operational focus was the continued development, maintenance, and support of the Faning platform. The Company operates its business through its core Faning platform and strategy.

Share on Social Networks: